About CanTx

Novel Approach To Abdominal Cancers

At CanTx, we believe that more effective cancer treatment is not only possible but urgently needed. We are a clinical-stage biopharmaceutical company dedicated to developing novel, well-tolerated, oral treatments for patients suffering from aggressive cancers where current options are insufficient. Our work is centered on a deep scientific understanding of cancer biology, enabling us to create therapies that target the disease at its core while minimizing the toxic side effects of traditional treatments.

We are pioneering new therapeutic strategies for complex and difficult-to-treat abdominal cancers, such as pancreatic cancer. Our lead clinical candidate, azeliragon, is an oral, once-daily medication that inhibits the Receptor for Advanced Glycation Endproducts (RAGE). Activation of RAGE by its various ligands is known to stimulate cancer progression, metastasis, and resistance to treatment. By blocking this pathway, azeliragon is designed to:

• Inhibit cancer growth and metastasis by disrupting a key driver of tumor spread.
• Enhance sensitivity to existing cancer treatments, potentially improving patient outcomes.
• Provide a well-tolerated therapy that can be used alongside other treatments, thereby improving quality of life for patients.